Charles River Laboratories International Inc Company News

Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

WILMINGTON, Mass., April 22, 2024--In addition to advancing human health and improving quality of life, we are dedicated to a responsible tomorrow.

Investors are optimistic about Charles River (CRL) owing to strength in RMS and DSA segments.

WILMINGTON, Mass., April 16, 2024--Charles River launches the Alternative Methods Advancement Project (AMAP), an initiative to develop alternatives to reduce animal testing.

ICLR vs. CRL: Which Stock Is the Better Value Option?

WILMINGTON, Mass., April 12, 2024--Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2024 financial results on Thursday, May 9th, before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 9th, at 8:30 a.m. ET.

Charles River (CRL) is set to perform plasmid production for Ship of Theseus.

WILMINGTON, Mass. & DUBLIN, April 11, 2024--Charles River and Deciphex launch Patholytix Foresight, an AI-powered decision support tool for toxicologic pathology.

WILMINGTON, Mass., April 09, 2024--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd. Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure.

WILMINGTON, Mass., April 04, 2024--Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus, a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement. Ship of Theseus will leverage Charles River’s premier expertise to manufacture GMP plasmid DNA to serve as the active drug substance for its lead candidate.

Charles River Laboratories International (NYSE:CRL) has had a great run on the share market with its stock up by a...

WILMINGTON, Mass., April 01, 2024--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that its industry-leading team of oncology experts will attend the American Association for Cancer Research (AACR) Annual Meeting. Charles River will present technology-driven capabilities and highlight the latest advancements in immuno-oncology, in vitro assays, and more. The meeting is taking place from April 5-10, 2024, at the San Diego Convention Center in San Diego, California.

WILMINGTON, Mass., March 27, 2024--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2023 Corporate Citizenship Report, which includes progress and results from 2022 and 2023. The 2023 report demonstrates Charles River’s priorities and commitments across its strategic Environmental, Social and Governance (ESG) areas of focus: Accelerate Life-Saving Therapies; Lead with Integrity; Inspire our People; and Protect our Planet.